18F-FDG PET/MRI联合前哨淋巴结SPECT/CT用于FIGO I/II期宫颈癌淋巴结分期
PET/MRI对淋巴结转移的特异性为100%(29/29;95%CI,88.3%-100%),但敏感性低,仅33.3%(4/12;95%CI,12.8%-60.9%)。PET/MRI联合SLN SPECT/CT可将盆腔淋巴结转移检出率从33.3%提高至75%。
要点
- PET/MRI对宫颈癌淋巴结转移特异性达100%,但敏感性仅33.3%。
- PET/MRI仅能识别>5 mm的淋巴结转移,≤5 mm者敏感性为0%。
- SLN SPECT/CT不可检出时恶性率更高(31.2% vs. 19.3%)。
核心结论
- 18F-FDG PET/MRI是高度特异的N分期方法,可提高淋巴结转移检出,但因对小转移灶敏感性有限,应与SLN示踪联合使用。
- 所提出的联合方案有助于判断FIGO I/II期宫颈癌患者是否需要广泛手术分期。
研究设计与样本
- 每例患者术前行全身18F-FDG PET/MRI及宫颈内注射99mTc标记纳米胶体后的SLN SPECT/CT成像。
- 以系统性淋巴结清扫和SLN活检为参考标准,PET/MRI分期由核医学与放射科专家共识判读。
主要发现
- 1例因PET/MRI新诊断肝转移被排除手术分期,其余41例淋巴结转移总患病率为29.3%(12/41)。
- 12例淋巴结转移中5例仅为最大直径5 mm的小转移。
- 共识判读显示PET/MRI对淋巴结转移分期的特异性为100%(29/29;95%CI,88.3%-100%),敏感性为33.3%(4/12;95%CI,12.8%-60.9%)。
- 淋巴结大小是转移可检出性的最重要因素,PET/MRI仅能识别>5 mm的淋巴结转移(>5 mm敏感性57.1%,≤5 mm敏感性0%)。
- 4例腹主动脉旁淋巴结转移患者中3例被PET/MRI准确评估;SLN SPECT/CT在82.9%的患者或69.0%的半盆腔中可检出。
关键数值与推荐
- PET/MRI对淋巴结转移特异性100%(29/29;95%CI,88.3%-100%),敏感性33.3%(4/12;95%CI,12.8%-60.9%)。
- PET/MRI对>5 mm淋巴结转移敏感性57.1%,对≤5 mm者敏感性0%。
- SLN SPECT/CT不可检出病例的恶性率为31.2%,可检出者为19.3%。
- PET/MRI联合SLN SPECT/CT将盆腔淋巴结转移检出率从33.3%提高至75%。
临床怎么用
- 对FIGO I/II期宫颈癌患者,PET/MRI高特异性可用于确认淋巴结状态,但阴性结果不能排除小转移。
- PET/MRI应与SLN SPECT/CT联合使用,以弥补其对≤5 mm转移敏感性不足的缺陷。
- 联合方案可辅助判断是否需要广泛手术分期,SLN SPECT/CT不可检出时需警惕更高恶性风险。
局限性
- 样本量较小,共41例可评估患者。
- PET/MRI对≤5 mm淋巴结转移敏感性为0%,小转移灶检出能力有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lymph node metastasis (LNM) is present in a minority of patients with early stages of cervical carcinomas. As conventional imaging including PET/CT has shown limited sensitivity, systematic lymphadenectomies are often conducted for staging purposes. Therefore, the aim of this prospective study was to analyze the impact of 18F-FDG PET/MRI in addition to sentinel lymph node (SLN) biopsy on lymph node (LN) status. Methods: Forty-two women with an initial diagnosis of Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) IA-IIB cervical carcinoma were included between March 2016 and April 2019. Each patient underwent preoperative whole-body 18F-FDG PET/MRI and SLN imaging with SPECT/CT after intracervical injection of 99mTc-labeled nanocolloid. Systematic lymphadenectomy and SLN biopsy served as the reference standard. Staging using PET/MRI was performed by nuclear medicine and radiology experts working in consensus. Results: One patient was excluded from surgical staging because of liver metastases newly diagnosed on PET/MRI. The overall prevalence of LNM in the remaining 41 patients was 29.3% (12/41). Five of 12 patients with LNM had solely small metastases with a maximum diameter of 5 mm. The consensus interpretation showed PET/MRI to have a specificity of 100% (29/29; 95% CI, 88.3%-100%) for LNM staging but a low sensitivity, 33.3% (4/12; 95% CI, 12.8%-60.9%). LN size was the most important factor for the detectability of metastases, since only LNMs larger than 5 mm could be identified by PET/MRI (sensitivity, 57.1% for >5 mm and 0% for ≤5 mm). Paraaortic LNM was evaluated accurately in 3 of the 4 patients with paraaortic LN metastasis. SLNs were detectable by SPECT/CT in 82.9% of the patients or 69.0% of the hemipelves. In cases with an undetectable SLN on SPECT/CT, the malignancy rate was considerably higher (31.2% vs. 19.3%). The combination of PET/MRI and SLN SPECT/CT improved the detection of pelvic LNM from 33.3% to 75%. Conclusion:18F-FDG PET/MRI is a highly specific N-staging method and improves LNM detection. Because of the limited sensitivity in frequently occurring small LNMs, PET/MRI should be combined with SLN mapping. The proposed combined protocol helps to decide whether extensive surgical staging is necessary in patients with FIGO I/II cervical cancer.
引用
- Weissinger M, Taran FA, Gatidis S, et al. Lymph Node Staging with a Combined Protocol of 18F-FDG PET/MRI and Sentinel Node SPECT/CT: A Prospective Study in Patients with FIGO I/II Cervical Carcinoma. J Nucl Med. 2021. PMID: 33509973. doi:10.2967/jnumed.120.255919
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。